Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. [electronic resource]
Producer: 20111027Description: 1145-51 p. digitalISSN:- 1432-0584
- Aged
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- China -- epidemiology
- Cohort Studies
- Disease Susceptibility -- chemically induced
- Drug Monitoring
- Female
- Humans
- Incidence
- Lung Diseases, Interstitial -- complications
- Lymphocyte Count
- Lymphoma, Large B-Cell, Diffuse -- blood
- Lymphopenia -- etiology
- Male
- Middle Aged
- Retrospective Studies
- Risk Factors
- Rituximab
- Survival Analysis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.